Thomas K Eigentler
Overview
Explore the profile of Thomas K Eigentler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
3518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796786
There was an error in the original publication [...].
2.
Weihmann K, Schleusener J, Eigentler T, Ghoreschi F, Moritz R, Szyc L, et al.
Skin Pharmacol Physiol
. 2024 Dec;
37(4-6):97-103.
PMID: 39622207
Introduction: Dermatofluoroscopy is an optical noninvasive method of melanoma/nevus differentiation that has shown 89% sensitivity and 45% specificity in clinical trials, but long measurement duration hinders clinical use. An intelligent...
3.
Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123397
Background: The prevalence of metastatic melanoma is increasing, necessitating the identification of patients who do not benefit from immunotherapy. This study aimed to develop a radiomic biomarker based on the...
4.
Rischin D, Hughes B, Basset-Seguin N, Schadendorf D, Bowyer S, Trabelsi Messai S, et al.
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38471711
Background: Cemiplimab (Libtayo), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who...
5.
Rogava M, Aprati T, Chi W, Melms J, Hug C, Davis S, et al.
Nat Cancer
. 2024 Jan;
5(3):433-447.
PMID: 38286827
Liver metastasis (LM) confers poor survival and therapy resistance across cancer types, but the mechanisms of liver-metastatic organotropism remain unknown. Here, through in vivo CRISPR-Cas9 screens, we found that Pip4k2c...
6.
Abele M, Forchhammer S, Eigentler T, Popescu A, Maschke L, Lohse J, et al.
Pediatr Blood Cancer
. 2024 Jan;
71(4):e30859.
PMID: 38225622
Background: Melanomas of the central nervous system (CNS) based on neurocutaneous melanocytosis (NCM) are exceptionally rare in childhood and have been described only sporadically. Rapidly progressive disease may represent a...
7.
Wagner N, Knierim S, Luttermann F, Metzler G, Yazdi A, Bauer J, et al.
J Am Acad Dermatol
. 2023 Dec;
90(4):739-748.
PMID: 38043594
Background: Histopathologic regression of cutaneous melanoma is considered a favorable prognostic factor, but its significance in clinical practice remains controversial. Objective: To investigate the prognostic importance of regression in patients...
8.
Wagner N, Lenders M, Kuhl K, Reinhardt L, Fuchss M, Ring N, et al.
Eur J Cancer
. 2023 Dec;
196:113425.
PMID: 38039778
Background: Targeted therapy (TT) of BRAF V600 mutated unresectable melanoma with inhibitors of the MAPK pathway achieves response rates of up to 76%, but most patients develop secondary resistance. Albeit...
9.
Peisen F, Gerken A, Hering A, Dahm I, Nikolaou K, Gatidis S, et al.
Diagnostics (Basel)
. 2023 Oct;
13(20).
PMID: 37892030
Background: The aim of this study was to investigate whether the combination of radiomics and clinical parameters in a machine-learning model offers additive information compared with the use of only...
10.
Berking C, Livingstone E, Debus D, Loquai C, Weichenthal M, Leiter U, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760406
Combined BRAF/MEK-inhibition constitutes a relevant treatment option for -mutated advanced melanoma. The prospective, non-interventional COMBI-r study assessed the effectiveness and tolerability of the BRAF-inhibitor dabrafenib combined with the MEK-inhibitor trametinib...